Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector

17 Jul 2025

Abstract excerpt

Chimeric antigen receptor (CAR) T cell therapy has proved remarkably successful for the treatment of hematological malignancies. However, the bespoke manufacturing of autologous CAR T cells is complex and expensive. The development of methods for in vivo engineering of T cells will enable generation of CAR T cells directly within the patient, bypassing the need for ex vivo manufacturing and thereby enabling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40676833
DOI: 10.1016/j.ymthe.2025.07.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vectorPMID 40676833Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read ↗

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read ↗

Engineering of CAR-less lentiviral vectors via ER retention-mediated CAR blockadeSemantic proximity Read ↗

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T CellsSemantic proximity Read ↗

Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generationSemantic proximity Read ↗

In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligandSemantic proximity Read ↗

Adeno‐Associated Viral Vectors for Homology‐Directed Generation of CAR‐T CellsSemantic proximity Read ↗

Multipurposing CARs: Same engine, different vehiclesSemantic proximity Read ↗

Transduction of Human T Cell Subsets with Lentivirus.Semantic proximity Read ↗

Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In VivoSemantic proximity Read ↗

Clinical use of lentiviral vectorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.